Back to Search
Start Over
MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC.
- Source :
- Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS161-S161, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 15560864
- Volume :
- 18
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173322833
- Full Text :
- https://doi.org/10.1016/j.jtho.2023.09.236